These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Switches of antiepileptic drug products come under fire. Thompson CA Am J Health Syst Pharm; 2009 Jul; 66(14):1243-4. PubMed ID: 19574591 [No Abstract] [Full Text] [Related]
44. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100 [TBL] [Abstract][Full Text] [Related]
45. Comment: Pharmacy and generic substitution of antiepileptic drugs: missing in action? Hatton RC Ann Pharmacother; 2007 Sep; 41(9):1550-1; author reply 1551-2. PubMed ID: 17652128 [No Abstract] [Full Text] [Related]
46. [Generic carbamazepine-induced subacute adrenal insufficiency?]. Vergely N; Mounier C; Guy C; Millot L; Estour B Ann Med Interne (Paris); 2002 Nov; 153(7):481-2. PubMed ID: 12598835 [TBL] [Abstract][Full Text] [Related]
47. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Wilner AN Epilepsy Behav; 2004 Dec; 5(6):995-8. PubMed ID: 15582850 [TBL] [Abstract][Full Text] [Related]
48. [Treatment of epilepsies for general practitioners]. Stefan H MMW Fortschr Med; 2009 Mar; 151(13):49-52. PubMed ID: 19504819 [No Abstract] [Full Text] [Related]
49. [Change from original preparations to generics. A case example with oxcarbazepine]. Hagemann G; Zinke J; Fuchs M; Witte OW Nervenarzt; 2010 Dec; 81(12):1498-500. PubMed ID: 20509018 [No Abstract] [Full Text] [Related]
50. Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Krämer G; Steinhoff BJ; Feucht M; Pfäfflin M; May TW Epilepsia; 2007 Mar; 48(3):609-11. PubMed ID: 17346253 [No Abstract] [Full Text] [Related]
51. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN Seizure; 2017 May; 48():1-6. PubMed ID: 28363098 [TBL] [Abstract][Full Text] [Related]
52. Assessing bioequivalence of generic antiepilepsy drugs by indirect comparisons. García Arieta A Ann Neurol; 2012 May; 71(5):724-5; author reply 725. PubMed ID: 22473748 [No Abstract] [Full Text] [Related]
53. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Perron R Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865 [No Abstract] [Full Text] [Related]
54. [Generic drugs: any doubt no longer allowed]. Chast F Rev Prat; 2013 Apr; 63(4):452-4. PubMed ID: 23682462 [No Abstract] [Full Text] [Related]
56. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743 [TBL] [Abstract][Full Text] [Related]
57. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Wiberg CC Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15851759 [No Abstract] [Full Text] [Related]
58. [The war on generic drugs]. Sternon J Rev Med Brux; 2006; 27(5):420-1. PubMed ID: 17176536 [No Abstract] [Full Text] [Related]
59. [Clinical pharmacokinetics of carbamazepine (review of the literature)]. Martynova LA; Puzin MN; Seleznev AN Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(10):145-8. PubMed ID: 2694702 [No Abstract] [Full Text] [Related]